Author Index Volume 2 (2015)
Abicht, A., see Ørstavik, K. (2) 181–184
Accorsi, A., T. Mehuron, A. Kumar, Y. Rhee and M. Girgenrath, Integrin dysregulation as a possible driver of matrix remodeling in Laminin-deficient congenital muscular dystrophy (MDC1A) (1) 51–61
Alexander, M.S. and L.M. Kunkel, “Skeletal Muscle MicroRNAs: Their Diagnostic and Therapeutic Potential in Human Muscle Diseases” (1) 1–11
Allamand, V., see Nelson, I. (3) 229–240
Allen, P., see Cacheux, M. (4) 421–432
Allenbach, Y. and O. Benveniste, Diagnostic Utility of Auto-Antibodies in Inflammatory Muscle Diseases (1) 13–25
Alston, C.L., see Wesolowska, M. (4) 409–419
Al-Zaidy, S.A., Z. Sahenk, L.R. Rodino-Klapac, B. Kaspar and J.R. Mendell, Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy (3) 185–192
Ander, B.P., see Liu, D.Z. (4) 387–396
Annoussamy, M., see Servais, L. (3) 269–279
Apponi, L.H., see Vest, K.E. (4) 439–446
Azzi, V., see Catteruccia, M. (4) 453–462
Babuty, D., see Nelson, I. (3) 229–240
Banerjee, A., see Vest, K.E. (4) 439–446
Barnett, C., I.S.J. Merkies, H. Katzberg and V. Bril, Psychometric Properties of the Quantitative Myasthenia Gravis Score and the Myasthenia Gravis Composite Scale (3) 301–311
Barnett, C., see Kassardjian, C.D. (1) 93–97
Barthélémy, F., C. Blouin, N. Wein, V. Mouly, S. Courrier, E. Dionnet, V. Kergourlay, Y. Mathieu, L. Garcia, G. Butler-Browne, C. Lamaze, N. Lévy, M. Krahn and M. Bartoli, Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients’ Cells (3) 281–290
Bartoli, M., see Barthélémy, F. (3) 281–290
Bartoli, M., see Cerino, M. (2) 131–136
Bates, M.G., see Newman, J. (2) 151–155
Battle, D., see Renusch, S.R. (2) 119–130
Bécane, H.-M., see Nelson, I. (3) 229–240
Beggs, A.H., see Ceyhan-Birsoy, O. (1) 87–92
Béhin, A., see Cerino, M. (2) 131–136
Bell, C.F., see Landfeldt, E. (1) 63–72
Bennett, D., see Burch, P.M. (3) 241–255
Benveniste, O., see Allenbach, Y. (1) 13–25
Bernard, R., see Cerino, M. (2) 131–136
Béroud, C., see Nelson, I. (3) 229–240
Bertini, E., see Catteruccia, M. (4) 453–462
Beuvin, M., see Malfatti, E. (3) 219–227
Biancalana, V. and J. Laporte, Diagnostic use of Massively Parallel Sequencing in Neuromuscular Diseases: Towards an Integrated Diagnosis (3) 193–203
Blouin, C., see Barthélémy, F. (3) 281–290
Blum, A., see Cacheux, M. (4) 421–432
Böhm, J., see Malfatti, E. (3) 219–227
Bonne, G., see Nelson, I. (3) 229–240
Bouchet-Séraphin, C., S. Vuillaumier-Barrot and N. Seta, Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein (1) 27–38
Breton, R., see Denicourt, M. (1) 99–105
Bril, V., see Barnett, C. (3) 301–311
Bril, V., see Kassardjian, C.D. (1) 93–97
Brocard, J., see Cacheux, M. (4) 421–432
Brochier, G., see Malfatti, E. (3) 219–227
Brochier, G., see Richard, P. (2) 175–180
Browne, G.B., see Thorley, M. (3) 205–217
Burch, P.M., O. Pogoryelova, R. Goldstein, D. Bennett, M. Guglieri, V. Straub, K. Bushby, H. Lochmüller and C. Morris, Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy (3) 241–255
Bushby, K., see Burch, P.M. (3) 241–255
Bushby, K., see Landfeldt, E. (1) 63–72
Butler-Browne, G., see Barthélémy, F. (3) 281–290
Butoianu, N., see Servais, L. (3) 269–279
Cacheux, M., A. Blum, M. Sébastien, A.S. Wozny, J. Brocard, K. Mamchaoui, V. Mouly, N. Roux-Buisson, J. Rendu, N. Monnier, R. Krivosic, P. Allen, A. Lacour, J. Lunardi, J. Fauré and I. Marty, Functional Characterization of a Central Core Disease RyR1 Mutation (p.Y4864H) Associated with Quantitative Defect in RyR1 Protein (4) 421–432
Campbell, C., see Wei, Y. (3) 313–324
Cances, C., see Servais, L. (3) 269–279
Carr, B., see Montes, J. (4) 463–470
Catteruccia, M., C. Vuillerot, I. Vaugier, D. Leclair, V. Azzi, L. Viollet, B. Estournet, E. Bertini and S. Quijano-Roy, Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children (4) 453–462
Cerino, M., S. Gorokhova, A. Béhin, J.A. Urtizberea, V. Kergourlay, E. Salvo, R. Bernard, N. Lévy, M. Bartoli and M. Krahn, Novel Pathogenic Variants in a French Cohort Widen the Mutational Spectrum of GNE Myopathy (2) 131–136
Ceyhan-Birsoy, O., B. Talim, L.C. Swanson, M. Karakaya, M.A. Graff, A.H. Beggs and H. Topaloglu, Whole Exome Sequencing Reveals DYSF, FKTN, and ISPD Mutations in Congenital Muscular Dystrophy Without Brain or Eye Involvement (1) 87–92
Chadwick, J.A., see Lowe, J. (3) 257–268
Chen, W., see Johnson, N.E. (4) 447–452
Chinnery, P.F., see Wesolowska, M. (4) 409–419
Chrzanowska-Lightowlers, Z.M., see Wesolowska, M. (4) 409–419
Ciafaloni, E., see Johnson, N.E. (4) 447–452
Corbett, A.H., see Vest, K.E. (4) 439–446
Courrier, S., see Barthélémy, F. (3) 281–290
Cruz, R., see Montes, J. (4) 463–470
Cuisset, J.-M., see Servais, L. (3) 269–279
de Groot, I.J.M., see van den Engel-Hoek, L. (4) 357–369
De Luca, A., see Willmann, R. (2) 113–117
de Swart, B.J.M., see van den Engel-Hoek, L. (4) 357–369
De Vivo, D.C., see Montes, J. (4) 463–470
Deenen, J.C.W., C.G.C. Horlings, J.J.G.M. Verschuuren, A.L.M. Verbeek and B.G.M. van Engelen, The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature (1) 73–85
Delmont, E. and H. Willison, Diagnostic Utility of Auto Antibodies in Inflammatory Nerve Disorders (2) 107–112
Delmont, E., see Galban-Horcajo, F. (2) 157–165
Demay, L., see Richard, P. (2) 175–180
Denicourt, M., M.T. Pham, J. Mathieu and R. Breton, DM1 Patients with Small CTG Expansions are also at Risk of Severe Conduction Abnormalities (1) 99–105
Dionnet, E., see Barthélémy, F. (3) 281–290
Duan, D., see Hakim, C.H. (4) 397–407
Duddy, W., see Thorley, M. (3) 205–217
Duguez, S., see Thorley, M. (3) 205–217
Dunaway, S., see Montes, J. (4) 463–470
Elsheikh, B.H., see Renusch, S.R. (2) 119–130
Erasmus, C.E., see van den Engel-Hoek, L. (4) 357–369
Estournet, B., see Catteruccia, M. (4) 453–462
Eymard, B., see Nelson, I. (3) 229–240
Eymard, B., see Richard, P. (2) 175–180
Fardeau, M., see Richard, P. (2) 175–180
Fauré, J., see Cacheux, M. (4) 421–432
Feng, F., see Hakim, C.H. (4) 397–407
Ferrer-Monasterio, X., see Richard, P. (2) 175–180
Floyd, K.T., see Lowe, J. (3) 257–268
Freitas, M.A., see Renusch, S.R. (2) 119–130
Fricke, A.F., see Statland, J.M. (3) 291–299
Galban-Horcajo, F., L. Vlam, E. Delmont, S.K. Halstead, L. van den Berg, W-L. van der Pol and H.J. Willison, The Diagnostic Utility of Determining Anti-GM1: GalC Complex Antibodies in Multifocal Motor Neuropathy: A Validation Study (2) 157–165
Galna, B., see Newman, J. (2) 151–155
Garber, C.E., see Montes, J. (4) 463–470
Garcia, L., see Barthélémy, F. (3) 281–290
Gardner, B.B., K.A. Swaggart, G. Kim, S. Watson and E.M. McNally, Cardiac function in muscular dystrophy associates with abdominal muscle pathology (1) 39–49
Gidaro, T., see Richard, P. (2) 175–180
Gidaro, T., see Servais, L. (3) 269–279
Girgenrath, M., see Accorsi, A. (1) 51–61
Goldstein, R., see Burch, P.M. (3) 241–255
Gorman, G.S., see Newman, J. (2) 151–155
Gorman, G.S., see Wesolowska, M. (4) 409–419
Gorokhova, S., see Cerino, M. (2) 131–136
Graff, M.A., see Ceyhan-Birsoy, O. (1) 87–92
Griffin, H., see Wesolowska, M. (4) 409–419
Guglieri, M., see Burch, P.M. (3) 241–255
Guglieri, M., see Landfeldt, E. (1) 63–72
Hagerman, K.A., see Johnson, N.E. (4) 447–452
Hakim, C.H., A.A. Peters, F. Feng, G. Yao and D. Duan, Night Activity Reduction is a Signature Physiological Biomarker for Duchenne Muscular Dystrophy Dogs (4) 397–407
Halicek, M.T., see Pfohl, S.R. (2) 137–150
Halstead, S.K., see Galban-Horcajo, F. (2) 157–165
Harshman, S., see Renusch, S.R. (2) 119–130
He, L., see Wesolowska, M. (4) 409–419
Heatwole, C.R., see Johnson, N.E. (4) 447–452
Henderson, D., see Statland, J.M. (3) 291–299
Hogrel, J.-Y., see Servais, L. (3) 269–279
Horlings, C.G.C., see Deenen, J.C.W. (1) 73–85
Hotta, A., Genome Editing Gene Therapy for Duchenne Muscular Dystrophy (4) 343–355
Hu, S., see Liu, D.Z. (4) 387–396
Hung, M., see Johnson, N.E. (4) 447–452
Hyzewicz, J., U.T. Ruegg and S. Takeda, Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients (4) 325–342
Jakovljevic, D.G., see Newman, J. (2) 151–155
Janssen, P.M.L., see Lowe, J. (3) 257–268
Jewell, D., see Kassardjian, C.D. (1) 93–97
Jickling, G.C., see Liu, D.Z. (4) 387–396
Johnson, N.E., M. Hung, E. Nasser, K.A. Hagerman, W. Chen, E. Ciafaloni and C.R. Heatwole, The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study (4) 447–452
Kamil-Rosenberg, S., see Montes, J. (4) 463–470
Karakaya, M., see Ceyhan-Birsoy, O. (1) 87–92
Kaspar, B., see Al-Zaidy, S.A. (3) 185–192
Kassardjian, C.D., S. Kokokyi, C. Barnett, D. Jewell, V. Bril, B.J. Murray and H.D. Katzberg, Excessive Daytime Sleepiness in Patients with Myasthenia Gravis (1) 93–97
Katzberg, H., see Barnett, C. (3) 301–311
Katzberg, H.D., see Kassardjian, C.D. (1) 93–97
Kergourlay, V., see Barthélémy, F. (3) 281–290
Kergourlay, V., see Cerino, M. (2) 131–136
Kerty, E., see Ørstavik, K. (2) 181–184
Kiiski, K., V-L. Lehtokari, A.Y. Manzur, C. Sewry, I. Zaharieva, F. Muntoni, K. Pelin and C. Wallgren-Pettersson, A Large Deletion Affecting TPM3, Causing Severe Nemaline Myopathy (4) 433–438
Kim, G., see Gardner, B.B. (1) 39–49
Kissel, J.T., see Renusch, S.R. (2) 119–130
Klein, A., see Servais, L. (3) 269–279
Kokokyi, S., see Kassardjian, C.D. (1) 93–97
Kolb, S.J., see Renusch, S.R. (2) 119–130
Krahn, M., see Barthélémy, F. (3) 281–290
Krahn, M., see Cerino, M. (2) 131–136
Kramer, S.S., see Montes, J. (4) 463–470
Krivosic, R., see Cacheux, M. (4) 421–432
Kumar, A., see Accorsi, A. (1) 51–61
Kunkel, L.M., see Alexander, M.S. (1) 1–11
Lacène, E., see Malfatti, E. (3) 219–227
Lacour, A., see Cacheux, M. (4) 421–432
Laforêt, P., see Richard, P. (2) 175–180
Lamaze, C., see Barthélémy, F. (3) 281–290
Landfeldt, E., P. Lindgren, C.F. Bell, C. Schmitt, M. Guglieri, V. Straub, H. Lochmüller and K. Bushby, Compliance to Care Guidelines for Duchenne Muscular Dystrophy (1) 63–72
Laporte, J., see Biancalana, V. (3) 193–203
Laporte, J., see Malfatti, E. (3) 219–227
Laugel, V., see Servais, L. (3) 269–279
Le Gall, L., see Thorley, M. (3) 205–217
Le Guiner, C., see Servais, L. (3) 269–279
Le Moing, A.-G., see Servais, L. (3) 269–279
Leclair, D., see Catteruccia, M. (4) 453–462
Lehtokari, V-L., see Kiiski, K. (4) 433–438
Leturcq, F., see Nelson, I. (3) 229–240
Leturcq, F., see Servais, L. (3) 269–279
Lévy, N., see Barthélémy, F. (3) 281–290
Lévy, N., see Cerino, M. (2) 131–136
Li, X., see Renusch, S.R. (2) 119–130
Lightowlers, R.N., see Wesolowska, M. (4) 409–419
Lindgren, P., see Landfeldt, E. (1) 63–72
Liu, D.Z., B. Stamova, S. Hu, B.P. Ander, G.C. Jickling, X. Zhan, F.R. Sharp and B. Wong, MicroRNA and mRNA Expression Changes in Steroid Naïve and Steroid Treated DMD Patients (4) 387–396
Lochmüller, H., see Burch, P.M. (3) 241–255
Lochmüller, H., see Landfeldt, E. (1) 63–72
Lowe, J., A.J. Wodarcyk, K.T. Floyd, N. Rastogi, E.J. Schultz, S.A. Swager, J.A. Chadwick, T. Tran, S.V. Raman, P.M.L. Janssen and J.A. Rafael-Fortney, The Angiotensin Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy (3) 257–268
Lunardi, J., see Cacheux, M. (4) 421–432
Malatras, A., see Thorley, M. (3) 205–217
Malfatti, E., J. Böhm, E. Lacène, M. Beuvin, G. Brochier, N.B. Romero and J. Laporte, A Premature Stop Codon in MYO18B is Associated with Severe Nemaline Myopathy with Cardiomyopathy (3) 219–227
Malfatti, E., see Richard, P. (2) 175–180
Mamchaoui, K., see Cacheux, M. (4) 421–432
Manzur, A.Y., see Kiiski, K. (4) 433–438
Martin-Négrier, M.-L., see Richard, P. (2) 175–180
Marty, I., see Cacheux, M. (4) 421–432
Mathieu, J., see Denicourt, M. (1) 99–105
Mathieu, Y., see Barthélémy, F. (3) 281–290
McFarland, R., see Newman, J. (2) 151–155
McNally, E.M., see Gardner, B.B. (1) 39–49
Mehuron, T., see Accorsi, A. (1) 51–61
Mendell, J.R., see Al-Zaidy, S.A. (3) 185–192
Merkies, I.S.J., see Barnett, C. (3) 301–311
Miller, J.A.L., see Wesolowska, M. (4) 409–419
Mitchell, C.S., see Pfohl, S.R. (2) 137–150
Monnier, N., see Cacheux, M. (4) 421–432
Montes, J., C.E. Garber, S.S. Kramer, M.J. Montgomery, S. Dunaway, S. Kamil-Rosenberg, B. Carr, R. Cruz, N.E. Strauss, D. Sproule and D.C. De Vivo, Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative? (4) 463–470
Montgomery, M.J., see Montes, J. (4) 463–470
Montus, M., see Servais, L. (3) 269–279
Moraux, A., see Servais, L. (3) 269–279
Morris, C., see Burch, P.M. (3) 241–255
Moullier, P., see Servais, L. (3) 269–279
Mouly, V., see Barthélémy, F. (3) 281–290
Mouly, V., see Cacheux, M. (4) 421–432
Mouly, V., see Thorley, M. (3) 205–217
Moyer, A.L. and K.R. Wagner, Mammalian Mss51 is a Skeletal Muscle-Specific Gene Modulating Cellular Metabolism (4) 371–385
MS Tomé, F., see Richard, P. (2) 175–180
Muntoni, F., see Kiiski, K. (4) 433–438
Murray, B.J., see Kassardjian, C.D. (1) 93–97
Nagaraju, K., see Willmann, R. (2) 113–117
Nasser, E., see Johnson, N.E. (4) 447–452
Nelson, I., T. Stojkovic, V. Allamand, F. Leturcq, H.-M. Bécane, D. Babuty, A. Toutain, C. Béroud, P. Richard, N.B. Romero, B. Eymard, R.B. Yaou and G. Bonne, Laminin α2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases (3) 229–240
Newman, J., B. Galna, D.G. Jakovljevic, M.G. Bates, A.M. Schaefer, R. McFarland, D.M. Turnbull, M.I. Trenell, R.W. Taylor, L. Rochester and G.S. Gorman, Preliminary Evaluation of Clinician Rated Outcome Measures in Mitochondrial Disease (2) 151–155
Odrzywolski, K.J., see Statland, J.M. (3) 291–299
Ørstavik, K., S.C. Wallace, T. Torbergsen, A. Abicht, S.E. Tangsrud, E. Kerty and M. Rasmussen, A de novo Mutation in the SCN4A Gene Causing Sodium Channel Myotonia (2) 181–184Pajak, A., see Wesolowska, M. (4) 409–419
Parthun, M.R., see Renusch, S.R. (2) 119–130
Pavlath, G.K., see Vest, K.E. (4) 439–446
Pelin, K., see Kiiski, K. (4) 433–438
Peters, A.A., see Hakim, C.H. (4) 397–407
Petri, H., see Werlauff, U. (2) 167–174
Pfohl, S.R., M.T. Halicek and C.S. Mitchell, Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis (2) 137–150
Pham, M.T., see Denicourt, M. (1) 99–105
Pi, H., see Renusch, S.R. (2) 119–130
Pogoryelova, O., see Burch, P.M. (3) 241–255
Prior, T.W., see Renusch, S.R. (2) 119–130
Pyle, A., see Wesolowska, M. (4) 409–419Quijano-Roy, S., see Catteruccia, M. (4) 453–462
Rafael-Fortney, J.A., see Lowe, J. (3) 257–268
Raman, S.V., see Lowe, J. (3) 257–268
Rasmussen, M., see Ørstavik, K. (2) 181–184
Rastogi, N., see Lowe, J. (3) 257–268
Rendu, J., see Cacheux, M. (4) 421–432
Renusch, S.R., S. Harshman, H. Pi, E. Workman, A. Wehr, X. Li, T.W. Prior, B.H. Elsheikh, K.J. Swoboda, L.R. Simard, J.T. Kissel, D. Battle, M.R. Parthun, M.A. Freitas and S.J. Kolb, Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults (2) 119–130
Rhee, Y., see Accorsi, A. (1) 51–61
Richard, P., C. Trollet, T. Gidaro, L. Demay, G. Brochier, E. Malfatti, F. MS Tomé, M. Fardeau, P. Laforêt, N. Romero, M.-L. Martin-Négrier, G. Solé, X. Ferrer-Monasterio, J.L. Saint-Guily and B. Eymard, PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy – Consequences in Clinical Diagnosis and Genetic Counselling (2) 175–180
Richard, P., see Nelson, I. (3) 229–240
Rochester, L., see Newman, J. (2) 151–155
Rodino-Klapac, L.R., see Al-Zaidy, S.A. (3) 185–192
Romero, N., see Richard, P. (2) 175–180
Romero, N.B., see Malfatti, E. (3) 219–227
Romero, N.B., see Nelson, I. (3) 229–240
Roux-Buisson, N., see Cacheux, M. (4) 421–432
Rüegg, M.A., see Willmann, R. (2) 113–117
Ruegg, U.T., see Hyzewicz, J. (4) 325–342
Sabouraud, P., see Servais, L. (3) 269–279
Sahenk, Z., see Al-Zaidy, S.A. (3) 185–192
Saint-Guily, J.L., see Richard, P. (2) 175–180
Salvo, E., see Cerino, M. (2) 131–136
Schaefer, A.M., see Newman, J. (2) 151–155
Schaefer, A.M., see Wesolowska, M. (4) 409–419
Schmitt, C., see Landfeldt, E. (1) 63–72
Schultz, E.J., see Lowe, J. (3) 257–268
Sébastien, M., see Cacheux, M. (4) 421–432
Seferian, A.M., see Servais, L. (3) 269–279
Servais, L., M. Montus, C. Le Guiner, R.B. Yaou, M. Annoussamy, A. Moraux, J.-Y. Hogrel, A.M. Seferian, K. Zehrouni, A.-G. Le Moing, T. Gidaro, C. Vanhulle, V. Laugel, N. Butoianu, J.-M. Cuisset, P. Sabouraud, C. Cances, A. Klein, F. Leturcq, P. Moullier and T. Voit, Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype (3) 269–279
Seta, N., see Bouchet-Séraphin, C. (1) 27–38
Sewry, C., see Kiiski, K. (4) 433–438
Shah, B., see Statland, J.M. (3) 291–299
Sharp, F.R., see Liu, D.Z. (4) 387–396
Simard, L.R., see Renusch, S.R. (2) 119–130
Solé, G., see Richard, P. (2) 175–180
Speechley, K., see Wei, Y. (3) 313–324
Sproule, D., see Montes, J. (4) 463–470
Stamova, B., see Liu, D.Z. (4) 387–396
Statland, J.M., K.J. Odrzywolski, B. Shah, D. Henderson, A.F. Fricke, S. van der Maarel, S.J. Tapscott and R. Tawil, Immunohistochemical Characterization of Facioscapulohumeral Muscular Dystrophy Muscle Biopsies (3) 291–299
Stojkovic, T., see Nelson, I. (3) 229–240
Straub, V., see Burch, P.M. (3) 241–255
Straub, V., see Landfeldt, E. (1) 63–72
Strauss, N.E., see Montes, J. (4) 463–470
Swager, S.A., see Lowe, J. (3) 257–268
Swaggart, K.A., see Gardner, B.B. (1) 39–49
Swanson, L.C., see Ceyhan-Birsoy, O. (1) 87–92
Swoboda, K.J., see Renusch, S.R. (2) 119–130
Takeda, S., see Hyzewicz, J. (4) 325–342
Talim, B., see Ceyhan-Birsoy, O. (1) 87–92
Tangsrud, S.E., see Ørstavik, K. (2) 181–184
Tapscott, S.J., see Statland, J.M. (3) 291–299
Tawil, R., see Statland, J.M. (3) 291–299
Taylor, R.W., see Newman, J. (2) 151–155
Taylor, R.W., see Wesolowska, M. (4) 409–419
Thorley, M., A. Malatras, W. Duddy, L. Le Gall, V. Mouly, G.B. Browne and S. Duguez, Changes in Communication between Muscle Stem Cells and their Environment with Aging (3) 205–217
Topaloglu, H., see Ceyhan-Birsoy, O. (1) 87–92
Torbergsen, T., see Ørstavik, K. (2) 181–184
Toutain, A., see Nelson, I. (3) 229–240
Tran, T., see Lowe, J. (3) 257–268
Trenell, M.I., see Newman, J. (2) 151–155
Trollet, C., see Richard, P. (2) 175–180
Turnbull, D.M., see Newman, J. (2) 151–155
Urtizberea, J.A., see Cerino, M. (2) 131–136
van den Berg, L., see Galban-Horcajo, F. (2) 157–165
van den Engel-Hoek, L., I.J.M. de Groot, B.J.M. de Swart and C.E. Erasmus, Feeding and Swallowing Disorders in Pediatric Neuromuscular Diseases: An Overview (4) 357–369
van der Maarel, S., see Statland, J.M. (3) 291–299
van der Pol, W-L., see Galban-Horcajo, F. (2) 157–165
van Engelen, B.G.M., see Deenen, J.C.W. (1) 73–85
Vanhulle, C., see Servais, L. (3) 269–279
Vaugier, I., see Catteruccia, M. (4) 453–462
Verbeek, A.L.M., see Deenen, J.C.W. (1) 73–85
Verschuuren, J.J.G.M., see Deenen, J.C.W. (1) 73–85
Vest, K.E., L.H. Apponi, A. Banerjee, G.K. Pavlath and A.H. Corbett, An Antibody to Detect Alanine-Expanded PABPN1: A New Tool to Study Oculopharyngeal Muscular Dystrophy (4) 439–446
Viollet, L., see Catteruccia, M. (4) 453–462
Vissing, J., see Werlauff, U. (2) 167–174
Vlam, L., see Galban-Horcajo, F. (2) 157–165
Voit, T., see Servais, L. (3) 269–279
Vuillaumier-Barrot, S., see Bouchet-Séraphin, C. (1) 27–38
Vuillerot, C., see Catteruccia, M. (4) 453–462
Wagner, K.R., see Moyer, A.L. (4) 371–385
Wallace, S.C., see Ørstavik, K. (2) 181–184
Wallgren-Pettersson, C., see Kiiski, K. (4) 433–438
Watson, S., see Gardner, B.B. (1) 39–49
Wehr, A., see Renusch, S.R. (2) 119–130
Wei, Y., K. Speechley and C. Campbell, Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review (3) 313–324
Wein, N., see Barthélémy, F. (3) 281–290
Werlauff, U., H. Petri, N. Witting and J. Vissing, Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients with Congenital Myopathy Older than 5 Years (2) 167–174
Wesolowska, M., G.S. Gorman, C.L. Alston, A. Pajak, A. Pyle, L. He, H. Griffin, P.F. Chinnery, J.A.L. Miller, A.M. Schaefer, R.W. Taylor, R.N. Lightowlers and Z.M. Chrzanowska-Lightowlers, Adult Onset Leigh Syndrome in the Intensive Care Setting: A Novel Presentation of a C12orf65 Related Mitochondrial Disease (4) 409–419
Willison, H., see Delmont, E. (2) 107–112
Willison, H.J., see Galban-Horcajo, F. (2) 157–165
Willmann, R., A. De Luca, K. Nagaraju and M.A. Rüegg, Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders (2) 113–117
Witting, N., see Werlauff, U. (2) 167–174
Wodarcyk, A.J., see Lowe, J. (3) 257–268
Wong, B., see Liu, D.Z. (4) 387–396
Workman, E., see Renusch, S.R. (2) 119–130
Wozny, A.S., see Cacheux, M. (4) 421–432
Yao, G., see Hakim, C.H. (4) 397–407
Yaou, R.B., see Nelson, I. (3) 229–240
Yaou, R.B., see Servais, L. (3) 269–279
Zaharieva, I., see Kiiski, K. (4) 433–438
Zehrouni, K., see Servais, L. (3) 269–279
Zhan, X., see Liu, D.Z. (4) 387–396
